Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (31-40 of 246) with videos related to

Pageof 25
Sort By:
Clinical Drug Investigation|October 5, 2007
Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusionPaul L M van Giersbergen, Jasper Dingemanse
British Journal of Clinical Pharmacology|March 5, 2004
Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bileJasper Dingemanse, Paul L M van Giersbergen
Journal of Clinical Pharmacology|January 16, 2016
CYP2C9 involvement in ACT-453859 metabolismMartine Géhin, Jasper Dingemanse, Patricia N Sidharta
Clinical Drug Investigation|May 28, 2014
Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjectsPatricia N Sidharta, Hartmut Dietrich, Jasper Dingemanse
Frontiers in Pharmacology|February 22, 2021
Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral VasospasmPierre-Eric Juif, Jasper Dingemanse, Mike Ufer
European Journal of Drug Metabolism and Pharmacokinetics|September 25, 2003
Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjectsPaul L M Van Giersbergen, Jasper Dingemanse
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 18, 2014
Validation of an LC-MS/MS method for the quantitative determination of the orexin receptor antagonist almorexant and its four primary metabolites in human plasmaWinfried Wagner-Redeker, Isabel Finsterwald, Jasper Dingemanse
Expert Opinion on Drug Metabolism & Toxicology|January 22, 2015
Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertensionPatricia N Sidharta, Stephan Krähenbühl, Jasper Dingemanse
Pharmacology|May 19, 2016
Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma AnalysisMartine Géhin, Patricia N Sidharta, Jasper Dingemanse
Clinical Drug Investigation|August 23, 2019
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function ImpairmentPatricia N Sidharta, Ivan Ulč, Jasper Dingemanse
Pageof 25

Showing results (31-40 of 246) with videos related to

Sort By:
Pageof 25
Clinical Drug Investigation|October 5, 2007
Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusionPaul L M van Giersbergen, Jasper Dingemanse
British Journal of Clinical Pharmacology|March 5, 2004
Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bileJasper Dingemanse, Paul L M van Giersbergen
Journal of Clinical Pharmacology|January 16, 2016
CYP2C9 involvement in ACT-453859 metabolismMartine Géhin, Jasper Dingemanse, Patricia N Sidharta
Clinical Drug Investigation|May 28, 2014
Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjectsPatricia N Sidharta, Hartmut Dietrich, Jasper Dingemanse
Frontiers in Pharmacology|February 22, 2021
Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral VasospasmPierre-Eric Juif, Jasper Dingemanse, Mike Ufer
European Journal of Drug Metabolism and Pharmacokinetics|September 25, 2003
Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjectsPaul L M Van Giersbergen, Jasper Dingemanse
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 18, 2014
Validation of an LC-MS/MS method for the quantitative determination of the orexin receptor antagonist almorexant and its four primary metabolites in human plasmaWinfried Wagner-Redeker, Isabel Finsterwald, Jasper Dingemanse
Expert Opinion on Drug Metabolism & Toxicology|January 22, 2015
Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertensionPatricia N Sidharta, Stephan Krähenbühl, Jasper Dingemanse
Pharmacology|May 19, 2016
Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma AnalysisMartine Géhin, Patricia N Sidharta, Jasper Dingemanse
Clinical Drug Investigation|August 23, 2019
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function ImpairmentPatricia N Sidharta, Ivan Ulč, Jasper Dingemanse
Pageof 25